{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:25:04Z","timestamp":1777530304115,"version":"3.51.4"},"reference-count":72,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T00:00:00Z","timestamp":1568160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2019.00965","type":"journal-article","created":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T13:08:46Z","timestamp":1568207326000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":36,"title":["Adverse Events in Patients With Rheumatoid Arthritis and Psoriatic Arthritis Receiving Long-Term Biological Agents in a Real-Life Setting"],"prefix":"10.3389","volume":"10","author":[{"given":"Mayara Costa","family":"de Camargo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruna Cipriano Almeida","family":"Barros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izabela","family":"Fulone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus Tolentino","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam Sanches do Nascimento","family":"Silveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iara Alves de","family":"Camargo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvio","family":"Barberato-Filho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando de S\u00e1","family":"Del Fiol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciane Cruz","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2019,9,11]]},"reference":[{"key":"B1","unstructured":"Portaria n\u00b0. 66, de 6 de novembro de 2006. Health Tecnology and Strategy Drugs Secretariat. Clinical Protocol and Guidelines- Rheumatoid Arthrist Di\u00e1rio Oficial da Uni\u00e3o2006"},{"key":"B2","unstructured":"Artrite Psori\u00e1tica. Protocolo Cl\u00ednico e Diretrizes Terap\u00eauticas. Portaria SAS\/MS n\u00b0 1.204, de 4 de novembro de 20142014"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.3899\/jrheum.110207","article-title":"Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs","volume":"39","author":"Bykerk","year":"2012","journal-title":"J. Rheumatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1016\/j.clinthera.2016.02.020","article-title":"Gap between official guidelines and clinical practice for the treatment of rheumatoid arthritis in S\u00e3o Paulo, Brazil","volume":"38","author":"Camargo","year":"2016","journal-title":"Clin. Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"iii","DOI":"10.3310\/hta10420","article-title":"A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness","volume":"10","author":"Chen","year":"2006","journal-title":"Health Technol. Assess."},{"key":"B6","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/978-3-642-00663-0_16","article-title":"Mechanisms of adverse drug reactions to biologics","volume":"196","author":"Clarke","year":"2010","journal-title":"Handb. Exp. Pharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/rheumatology\/ket187","article-title":"The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics","volume":"52","author":"Coates","year":"2013","journal-title":"Rheumatol. (Oxf. Engl.)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"B9","first-page":"212","article-title":"Hypersensitivity reactions to biological drugs","volume":"24","author":"Corominas","year":"2014","journal-title":"J. Invest. Allergol. Clin. Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1136\/ard.2010.146365","article-title":"The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents","volume":"70","author":"Curtis","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s42358-018-0017-9","article-title":"The REAL study: a nationwide prospective study of rheumatoid arthritis in Brazil","volume":"58","author":"Da Rocha Castelar-Pinheiro","year":"2018","journal-title":"Adv. Rheumatol. (Lond. Engl.)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"c186","DOI":"10.1136\/bmj.c186","article-title":"The routine use of patient reported outcome measures in healthcare settings","volume":"340","author":"Dawson","year":"2010","journal-title":"BMJ"},{"key":"B13","doi-asserted-by":"publisher","first-page":"b702","DOI":"10.1136\/bmj.b702","article-title":"Management of rheumatoid arthritis: summary of NICE guidance","volume":"338","author":"Deighton","year":"2009","journal-title":"BMJ Br. Med. J."},{"key":"B14","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.rbr.2015.02.001","article-title":"Caracteriza\u00e7\u00e3o de pacientes com artrite reumatoide quanto a fatores de risco para doen\u00e7as vasculares card\u00edacas no Mato Grosso do Sul","volume":"55","author":"Deus","year":"2015","journal-title":"Rev. Bras. Reumatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00296-016-3436-0","article-title":"Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies","volume":"36","author":"Elyoussfi","year":"2016","journal-title":"Rheumatol. Int."},{"key":"B16","first-page":"20","article-title":"A practical approach to monitoring patients on biological agents for the treatment of psoriasis","volume":"3","author":"Emer","year":"2010","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S1553-7250(08)34073-2","article-title":"Adverse events during hospitalization: results of a patient survey","volume":"34","author":"Fowler","year":"2008","journal-title":"Jt. Comm. J. Qual. Patient Saf. Jt. Comm. Resour."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(13)60250-0","article-title":"Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial","volume":"381","author":"Gabay","year":"2013","journal-title":"Lancet (Lond. Engl.)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1093\/rheumatology\/keq242","article-title":"Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly","volume":"50","author":"Galloway","year":"2011","journal-title":"Rheumatol. (Oxf. Engl.)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"548","DOI":"10.3109\/08923973.2011.653646","article-title":"Safety of anti-TNF\u03b1 agents in the treatment of psoriasis and psoriatic arthritis","volume":"34","author":"Girolomoni","year":"2012","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1093\/rheumatology\/keu461","article-title":"Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis","volume":"54","author":"Gonzalez-Alvaro","year":"2015","journal-title":"Rheumatol. (Oxf.)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","article-title":"European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update","volume":"75","author":"Gossec","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1001\/jama.2011.1692","article-title":"Initiation of tumor necrosis factor-alpha antagonists and the risk of hospitalization for infection in patients with autoimmune diseases","volume":"306","author":"Grijalva","year":"2011","journal-title":"Jama"},{"key":"B24","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.mcna.2010.03.001","article-title":"The complex clinical picture of side effects to biologicals","volume":"94","author":"Hausmann","year":"2010","journal-title":"Med. Clin. North America"},{"key":"B25","first-page":"695","article-title":"Injection Site Reactions to Biologic Agents Used in Psoriasis and Psoriatic Arthritis","volume":"16","author":"Henderson Berg","year":"2017","journal-title":"J. Drugs Dermatol. JDD"},{"key":"B26","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1177\/1077558705279313","article-title":"Can patients be part of the solution? Views on their role in preventing medical errors","volume":"62","author":"Hibbard","year":"2005","journal-title":"Med. Care Res. Rev. MCRR"},{"key":"B27","unstructured":"E2A Clinical safety data management: definition and standards for expedited reporting1994"},{"key":"B28","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.semarthrit.2015.06.014","article-title":"Rituximab-induced serum sickness: a systematic review","volume":"45","author":"Karmacharya","year":"2015","journal-title":"Semin. Arthritis Rheum."},{"key":"B29","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.autrev.2010.07.005","article-title":"Drug-induced lupus: an update","volume":"10","author":"Katz","year":"2010","journal-title":"Autoimmun. Rev."},{"key":"B30","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jaad.2015.04.023","article-title":"Adverse events resulting in withdrawal of biologic therapy for psoriasis in real-world clinical practice: a Canadian multicenter retrospective study","volume":"73","author":"Kim","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"B31","first-page":"23","article-title":"Analysis of Characteristics about Spontaneous Reporting\u2014Reported in 2008","volume":"3","author":"Kim","year":"2010","journal-title":"JPERM"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.jaad.2008.01.006","article-title":"National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening","volume":"58","author":"Kimball","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1370\/afm.220","article-title":"Patient reports of preventable problems and harms in primary health care","volume":"2","author":"Kuzel","year":"2004","journal-title":"Ann. Family Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.jaci.2005.03.028","article-title":"Adverse reactions to biologic agents: focus on autoimmune disease therapies","volume":"116","author":"Lee","year":"2005","journal-title":"J. Allergy Clin. Immunol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1517\/14740338.2014.942219","article-title":"Patient reports of the frequency and severity of adverse reactions associated with biological agents prescribed for psoriasis in Brazil","volume":"13","author":"Lopes","year":"2014","journal-title":"Exp. Opin. Drug Safety"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1136\/ard.2010.149419","article-title":"Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis","volume":"70","author":"Mariette","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"B37","first-page":"34","article-title":"The variety of types of adverse side-effects during treatment with biological drugs","volume":"18","author":"Mazurek","year":"2012","journal-title":"Int. Rev. Allergol. Clin. Immunol. Family Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1136\/annrheumdis-2013-204851","article-title":"Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis","volume":"74","author":"Mercer","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"B39","article-title":"Psoriatic arthritis","author":"Michet","year":"2018"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/1756-185X.12264","article-title":"Factors associated with withdrawal of the anti-TNFalpha biologics in the treatment of rheumatic diseases: data from the Hong Kong Biologics Registry","volume":"17","author":"Mok","year":"2014","journal-title":"Int. J. Rheum. Dis"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1517\/14740338.2012.630388","article-title":"Update upon efficacy and safety of TNF-alpha inhibitors","volume":"11","author":"Murdaca","year":"2012","journal-title":"Exp. Opin. Drug Safety"},{"key":"B42","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1517\/14740338.2013.755957","article-title":"Selective TNF-alpha inhibitor-induced injection site reactions","volume":"12","author":"Murdaca","year":"2013","journal-title":"Exp. Opin. Drug Safety"},{"key":"B43","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1517\/14740338.2015.1009036","article-title":"Infection risk associated with anti-TNF-alpha agents: a review","volume":"14","author":"Murdaca","year":"2015","journal-title":"Exp. Opin. Drug Safety"},{"key":"B44","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin. Pharmacol. Ther."},{"key":"B45","doi-asserted-by":"publisher","first-page":"g7818","DOI":"10.1136\/bmj.g7818","article-title":"Patient reported outcome measures in practice","volume":"350","author":"Nelson","year":"2015","journal-title":"BMJ"},{"key":"B46","unstructured":"National Clinical Guideline Centre (UK). National Institute for Health and Clinical Excellence: GuidanceLondonRoyal College of Physicians (UK)2012"},{"key":"B47","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/nrrheum.2017.81","article-title":"Biologics registers in RA: methodological aspects, current role and future applications","volume":"13","author":"Nikiphorou","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1111\/j.1398-9995.2006.01058.x","article-title":"Adverse side-effects to biological agents","volume":"61","author":"Pichler","year":"2006","journal-title":"Allergy"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1007\/s10067-019-04516-2","article-title":"Changing rate of serious infections in biologic-exposed rheumatoid arthritis patients","volume":"38","author":"Ranza","year":"2019","journal-title":"Clin. Rheumatol"},{"key":"B50","unstructured":"Royal College of Nursing. Assessing, Managing and Monitoring Biologic Therapies for Inflammatory ArthritisRCN Guidance for Rheumatology Practitioners2017"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1136\/ard.2008.094946","article-title":"Treatment recommendations for psoriatic arthritis","volume":"68","author":"Ritchlin","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"B52","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/1741-7015-11-88","article-title":"Biologic therapy for autoimmune diseases: an update","volume":"11","author":"Rosman","year":"2013","journal-title":"BMC Med."},{"key":"B53","first-page":"1","article-title":"Caracteriza\u00e7\u00e3o cl\u00ednica de pacientes com artrite psori\u00e1sica","volume":"12","author":"Ruiz","year":"2014","journal-title":"Rev. Soc. Bras. Clin. Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1001\/jama.2011.1211","article-title":"Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials","volume":"306","author":"Ryan","year":"2011","journal-title":"Jama"},{"key":"B55","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1093\/rheumatology\/kel236","article-title":"Infections during tumour necrosis factor \u2014 \u03b1blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients","volume":"46","author":"Salliot","year":"2007","journal-title":"Rheumatol. (Oxf.)"},{"key":"B56","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/j.1610-0387.2010.07339.x","article-title":"Adverse drug reactions to biologics","volume":"8","author":"Scherer","year":"2010","journal-title":"J. Dtsch. Dermatol. Ges. J. Ger. Soc. Dermatol. JDDG"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12895-017-0063-8","article-title":"Rationale and desig of the Brigham cohort for psoriasis and psoriatic arthritis registy (COPPAR)","volume":"11","author":"Schneeweiss","year":"2017","journal-title":"BMC Dermatology"},{"key":"B58","doi-asserted-by":"publisher","first-page":"132","DOI":"10.4081\/reumatismo.2009.132","article-title":"MonitorNet: the Italian multi-centre observational study aimed at estimating the risk\/benefit profile of biologic agents in real-world rheumatology practice","volume":"61","author":"Sfriso","year":"2009","journal-title":"Reumatismo"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-004179","article-title":"Adherence to guidelines in the use of biological agents to treat psoriasis in Brazil","volume":"4","author":"Silveira","year":"2014","journal-title":"BMJ Open"},{"key":"B60","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1111\/j.1365-2133.2009.09505.x","article-title":"British Association of Dermatologists\u2019 guidelines for biologic interventions for psoriasis 2009","volume":"161","author":"Smith","year":"2009","journal-title":"Br. J. Dermatol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"CD008794","DOI":"10.1002\/14651858.CD008794.pub2","article-title":"Adverse effects of biologics: a network meta-analysis and Cochrane overview","volume":"2","author":"Singh","year":"2011","journal-title":"Cochrane database Syst. Rev."},{"key":"B62","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s11926-016-0609-5","article-title":"Infections With Biologics in Rheumatoid Arthritis and Related Conditions: a Scoping Review of Serious or Hospitalized Infections in Observational Studies","volume":"18","author":"Singh","year":"2016","journal-title":"Curr. Rheumatol. Rep."},{"key":"B63","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/pds.897","article-title":"Pharmacists\u2019 role in reporting adverse drug reactions in an international perspective","volume":"13","author":"Van Grootheest","year":"2004","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1136\/annrheumdis-2012-201956","article-title":"Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients","volume":"72","author":"Van Vollenhoven","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"B65","unstructured":"World Health Organization. Department of Essential Drugs and Medicines Policy. Safety of medicines. A guide to detecting and reporting adverse drug reactionsGenevaWorld Health Organization2002"},{"key":"B66","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1002\/acr.23781","article-title":"Long-Term Safety of Rituximab in Rheumatoid Arthritis: analysis from the SUNSTONE Registry","volume":"71","author":"Winthrop","year":"2018","journal-title":"Arthritis Care Res."},{"key":"B67","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s00393-012-1093-6","article-title":"The new 2012 German recommendations for treating rheumatoid arthritis: differences compared to the European standpoint","volume":"72","author":"Wollenhaupt","year":"2013","journal-title":"Z. Rheumatol."},{"key":"B68","article-title":"Rheumatoid arthritis","author":"Yazici","year":""},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0155517","article-title":"Predictive factors of spontaneous reporting of adverse drug reactions among community pharmacists","volume":"11","author":"Yu","year":"2016","journal-title":"PloS One"},{"key":"B70","first-page":"146","article-title":"The spectrum and types of adverse side effects to biological immune modulators: a proposal for new classification","volume":"53","author":"Zemkova","year":"2007","journal-title":"Folia Boil."},{"key":"B71","first-page":"893","article-title":"Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein","volume":"137","author":"Zeltser","year":"2001","journal-title":"Arch. Dermatol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1097\/MLR.0b013e31822047a8.","article-title":"Can we rely on patients\u2019 reports of adverse events","volume":"49","author":"Zhu","year":"2011","journal-title":"Med. Care"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2019.00965\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T17:44:27Z","timestamp":1569001467000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2019.00965\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,11]]},"references-count":72,"alternative-id":["10.3389\/fphar.2019.00965"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2019.00965","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,11]]},"article-number":"965"}}